Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) Invested Capital (2020 - 2025)

Historic Invested Capital for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to $347.1 million.

  • GeneDx Holdings' Invested Capital rose 3321.86% to $347.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $347.1 million, marking a year-over-year increase of 3321.86%. This contributed to the annual value of $251.0 million for FY2024, which is 713.99% up from last year.
  • Per GeneDx Holdings' latest filing, its Invested Capital stood at $347.1 million for Q3 2025, which was up 3321.86% from $332.3 million recorded in Q2 2025.
  • Over the past 5 years, GeneDx Holdings' Invested Capital peaked at $648.3 million during Q2 2022, and registered a low of -$565.2 million during Q2 2021.
  • For the 5-year period, GeneDx Holdings' Invested Capital averaged around $246.6 million, with its median value being $302.4 million (2023).
  • Its Invested Capital has fluctuated over the past 5 years, first skyrocketed by 794041.36% in 2021, then tumbled by 5448.0% in 2023.
  • GeneDx Holdings' Invested Capital (Quarter) stood at $399.1 million in 2021, then crashed by 34.85% to $260.0 million in 2022, then decreased by 9.88% to $234.3 million in 2023, then rose by 7.14% to $251.0 million in 2024, then skyrocketed by 38.26% to $347.1 million in 2025.
  • Its Invested Capital was $347.1 million in Q3 2025, compared to $332.3 million in Q2 2025 and $312.9 million in Q1 2025.